CRISPNA Bio S.L.

Genome editing has entered a new phase of precision with the emergence of CRISPNA Bio, a biotechnology venture rooted in a patented system developed at the University of Granada. The core innovation lies in replacing traditional RNA guides in CRISPR-Cas frameworks with peptide nucleic acids (PNAs), enhancing target specificity, stability, and sensitivity. This hybrid approach—merging CRISPR’s adaptability with PNA’s biochemical advantages—positions the technology for high-impact applications across gene therapy, diagnostics, and industrial biotechnology. In gene therapy, the system enables controlled genetic modifications, from correcting monogenic disorders to disrupting oncogenes or viral receptors, shifting paradigms from broad-spectrum interventions to cell-specific edits. Diagnostic applications leverage the technology’s sensitivity to detect tumor or pathogen biomarkers with improved accuracy. Beyond healthcare, the platform supports biotechnological process optimization, including novel product development. As a research-derived entity, the focus remains on commercializing this proprietary methodology, bridging laboratory breakthroughs with scalable solutions for therapeutic and analytical markets.